Synapse

← Meletios Α. Dimopoulos

Papers by Meletios Α. Dimopoulos

Page 3 · newest first

  1. Necrotizing Laryngitis in Patients with Hematologic Disease: The First Case-Report Due to PDR Acinetobacter baumannii and Literature ReviewMicroorganisms · 2024
  2. Central nervous system multiple myeloma: A real‐world multi‐institutional study of the Greek Myeloma Study GroupAmerican Journal of Hematology · 2024
  3. Ectopic Cushing syndrome in metastatic castration‑resistant prostate cancer: A case report and review of literatureOncology Letters · 2024
  4. The Interplay between the DNA Damage Response (DDR) Network and the Mitogen-Activated Protein Kinase (MAPK) Signaling Pathway in Multiple MyelomaInternational Journal of Molecular Sciences · 2024
  5. Low circulating tumor cell levels correlate with favorable outcomes and distinct biological features in multiple myelomaAmerican Journal of Hematology · 2024
  6. Ixazomib plus daratumumab and dexamethasone: Final analysis of a phase 2 study among patients with relapsed/refractory multiple myelomaAmerican Journal of Hematology · 2024
  7. Results from the randomized phase 3 DREAMM-8 study of belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide plus bortezomib and dexamethasone (PVd) in relapsed/refractory multiple myeloma (RRMM).Journal of Clinical Oncology · 2024
  8. ciRS‐7 circular RNA overexpression in plasma cells is a promising molecular biomarker of unfavorable prognosis in multiple myelomaeJHaem · 2024
  9. Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple MyelomaNew England Journal of Medicine · 2024
  10. Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple MyelomaNew England Journal of Medicine · 2024
  11. Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple MyelomaNew England Journal of Medicine · 2024
  12. Daratumumab (DARA) + bortezomib/lenalidomide/dexamethasone (VRd) in transplant-eligible (TE) patients (pts) with newly diagnosed multiple myeloma (NDMM): Analysis of minimal residual disease (MRD) in the PERSEUS trial.Journal of Clinical Oncology · 2024
  13. Efficacy of venetoclax-dexamethasone (VenDex) v pomalidomide-dexamethasone (PomDex) in patients (Pts) with t(11;14)-positive relapsed/refractory multiple myeloma [t(11;14)+ RRMM]: Phase 3 CANOVA study biomarker subgroup analysis.Journal of Clinical Oncology · 2024
  14. Phase 3 study results of isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRd) versus VRd for transplant-ineligible patients with newly diagnosed multiple myeloma (IMROZ).Journal of Clinical Oncology · 2024
  15. Evaluation of a novel method to guide belantamab mafodotin dosing in multiple myeloma based on a patient-reported questionnaire.Journal of Clinical Oncology · 2024
  16. DREAMM-7 update: Subgroup analyses from a phase 3 trial of belantamab mafodotin (belamaf) + bortezomib and dexamethasone (BVd) vs daratumumab, bortezomib, and dexamethasone (DVd) in relapsed/refractory multiple myeloma (RRMM).Journal of Clinical Oncology · 2024
  17. The Prognostic Role of BRD4 Expression in High-Grade Serous Ovarian CancerCancers · 2024
  18. The Interplay between the DNA Damage Response (DDR) Network and the Mitogen-Activated Protein Kinase (MAPK) Signaling Pathway in Multiple Myeloma2024
  19. Possible prognostic role of BMI before chemotherapy in the outcomes of women with ovarian cancerEndocrine Abstracts · 2024
  20. Impact of prior treatment on selinexor, bortezomib, dexamethasone outcomes in patients with relapsed/refractory multiple myeloma: Extended follow‐up subgroup analysis of the BOSTON trialEuropean Journal Of Haematology · 2024
  21. Progression-free survival as a surrogate endpoint for overall survival in patients with relapsed or refractory multiple myelomaBMC Cancer · 2024
  22. Implications and hidden toxicity of cardiometabolic syndrome and early‐stage heart failure in carfilzomib‐induced cardiotoxicityBritish Journal of Pharmacology · 2024
  23. Oral SERDs alone or in combination with CDK 4/6 inhibitors in breast cancer: Current perspectives and clinical trialsThe Breast · 2024
  24. Early microvascular coronary endothelial dysfunction precedes pembrolizumab-induced cardiotoxicity. Preventive role of high dose of atorvastatinBasic Research in Cardiology · 2024
  25. Characteristics and Outcomes of Patients With Relapsed/Refractory Multiple Myeloma After Exposure to Lenalidomide in First Line of Therapy: A Single Center Database Review in GreeceClinical Lymphoma Myeloma & Leukemia · 2024
  26. An open-label phase 2 study treating patients with first or second relapse of multiple myeloma with carfilzomib, pomalidomide, and dexamethasone (KPd): SELECT studyLeukemia & lymphoma/Leukemia and lymphoma · 2024
  27. Health-related quality of life in relapsed/refractory multiple myeloma treated with melflufen and dexamethasone: analyses from the phase III OCEAN studyHaematologica · 2024
  28. Small RNA‐seq and clinical evaluation of tRNA‐derived fragments in multiple myeloma: Loss of mitochondrial i‐tRFHisGTG results in patients' poor treatment outcomeBritish Journal of Haematology · 2024
  29. Low circulating tumor cell levels correlate with favorable outcomes and distinct biological features in multiple myeloma2024
  30. Belantamab mafodotin: an important treatment option for vulnerable patients with triple class exposed relapsed and/or refractory multiple myelomaHaematologica · 2024
  31. Abstract No. 213 Cephalic Arch Stenosis in Vascular Access: Single-Center Experience of 90 ProceduresJournal of Vascular and Interventional Radiology · 2024
  32. Abstract No. 212 The Use of Covered Stents for the Treatment of Symptomatic Central Venous Stenosis in Vascular Access. A Meta-Analysis of 6 Studies and 207 PatientsJournal of Vascular and Interventional Radiology · 2024
  33. Abstract No. 507 Sharp Recanalization of Central Venous Occlusion of the Thorax in Hemodialysis Patients: A Meta-Analysis of 320 CasesJournal of Vascular and Interventional Radiology · 2024
  34. Abstract No. 393 Use of Covered Stents for the Treatment of the Dysfunctional Vascular Access. A Single-Center Retrospective Analysis of 356 Patients and 621 ProceduresJournal of Vascular and Interventional Radiology · 2024
  35. Unraveling the Role of the NLRP3 Inflammasome in Lymphoma: Implications in Pathogenesis and Therapeutic StrategiesInternational Journal of Molecular Sciences · 2024
  36. Belantamab mafodotin, lenalidomide and dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma: Part 1 results of a phase I/II studyHaematologica · 2024
  37. Carfilzomib, daratumumab, and dexamethasone (KdD) vs. lenalidomide-sparing pomalidomide-containing triplet regimens for relapsed/refractory multiple myeloma: an indirect treatment comparisonLeukemia & lymphoma/Leukemia and lymphoma · 2024
  38. Thrombotic and bleeding complications in patients with AL amyloidosisBritish Journal of Haematology · 2024
  39. Efficacy and immune modulation associated with the addition of IMiDs to Daratumumab backbone in multiple myeloma patients refractory to both drug classes: resetting synergistic activityBlood Cancer Journal · 2024
  40. Biomarker analysis of the ASPEN study comparing zanubrutinib with ibrutinib for patients with Waldenström macroglobulinemiaBlood Advances · 2024
  41. Genetic justification ofCOVID‐19 patient outcomes usingDERGA, a novel data ensemble refinement greedy algorithmJournal of Cellular and Molecular Medicine · 2024
  42. Isatuximab-pomalidomide-dexamethasone versus pomalidomide-dexamethasone in patients with relapsed and refractory multiple myeloma: final overall survival analysisHaematologica · 2024
  43. Single‐cell analysis of MYD88L265P and MYD88WT Waldenström macroglobulinemia patientsHemaSphere · 2024
  44. Efficacy and safety of daratumumab with ixazomib and dexamethasone in lenalidomide‐exposed patients after one prior line of therapy: Final results of the phase 2 study DARIAAmerican Journal of Hematology · 2024
  45. Exploring the molecular biomarker utility of circCCT3 in multiple myeloma: A favorable prognostic indicator, particularly for R‐ISS II patientsHemaSphere · 2024
  46. Left ventricular myocardial work improves in response to treatment and is associated with survival among patients with light chain cardiac amyloidosisEuropean Heart Journal - Cardiovascular Imaging · 2023
  47. Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple MyelomaNew England Journal of Medicine · 2023
  48. Predictors of early morbidity and mortality in newly diagnosed multiple myeloma: data from five randomized, controlled, phase III trials in 3700 patientsLeukemia · 2023
  49. Daratumumab for patients with myeloma with early or late relapse after initial therapy: subgroup analysis of CASTOR and POLLUXBlood Advances · 2023
  50. Rapid transient and longer-lasting innate cytokine changes associated with adaptive immunity after repeated SARS-CoV-2 BNT162b2 mRNA vaccinationsFrontiers in Immunology · 2023